A record 323 drugs were in shortage in the first three months of 2024, affecting several countries including the US, France, Egypt, and India.

All drug classes are vulnerable to shortages, particularly sterile injectables, cancer chemotherapy, and emergency drugs.

The five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, intravenous fluids, and 32 chemotherapy drugs.

Most treatment shortages last over two years, affecting at least half a million patients, often elderly.

Manufacturing and quality problems are often the root cause of drug shortages, rather than just growing demand.

The FDA blames manufacturing issues, supply chain gaps, and downtime for drug shortages.

Large health systems often place large orders at the first sign of shortages, adding to the stress.

Lack of transparency in the supply chain can exacerbate drug shortages.

Requiring manufacturers to disclose suppliers, like in New Zealand, could help address drug shortages by increasing supply chain transparency.

The American Society of Health System Pharmacists has concerns about a proposal to address drug shortages, citing unfair financial sanctions on under-resourced hospitals.

Managing shortages is not enough and more federal work is needed to address the root causes of the crisis.

The White House proposes spending $3.26 billion to $5.11 billion over the next decade to address the nation's drug shortage.

Policymakers recommend giving the FDA more power to access drug shortage information.

The American Society of Health System Pharmacists is working with the federal government to address the drug shortage by promoting supply chain transparency and diversity.

The price of an imported insulin pen in Egypt has risen from 62 to 192 pounds due to a shortage.

Insulin costs 40 pounds locally, but is only available by prescription at the ambulance pharmacy for those with proven diabetes.

Egypt's medicine shortage is caused by high raw material prices due to a high exchange rate, as most are imported.

Egypt produces insulin, but the local product is not widely available.

Citizens' preference for imported medicines contributes to a shortage of local alternatives.

The director of the Center for Pharmaceutical Studies has called for awareness about local medicines and legislation to prevent over-the-counter dispensing without a prescription.

The private sector dominates Egypt's medicine market at 70%, with the government holding 30%, although much of its share is lost to the black market.

The high dollar price has led some factories to halt production, contributing to a medicine shortage, particularly for chronic diseases.

The state is urged to support private sector factories and develop a national strategy to localize the drug industry.

Essential medicines, including insulin, should be stockpiled for at least 6 months.

Activists and health experts have appealed to Prime Minister Narendra Modi to address India's ongoing anti-TB drug shortages.

The shortages are affecting drugs for treating drug-sensitive tuberculosis.

The shortages have grave implications, including treatment disruptions and increased risk of drug-resistant TB.

State-level logistical and bureaucratic issues are exacerbating the problem.

TB patients face challenges adhering to treatment due to drug shortages.

Many patients face a financial burden from buying medication out-of-pocket due to drug unavailability.

The persistence of the issue highlights the need for a transparent and accountable approach to addressing the shortages.

The government is being urged to ensure an uninterrupted supply of critical TB drugs.

India has the highest global burden of tuberculosis, drawing international attention to its response.

Resolving the anti-TB drug shortage crisis requires immediate governmental intervention and a long-term commitment to strengthening India's healthcare infrastructure.

The current system for addressing medication shortages is insufficient.

This can include increasing supply chain transparency, improving manufacturer-provider communication, and supporting affected patients.

Policymakers can address the root causes of medication shortages and develop prevention strategies.

Technology, like artificial intelligence, can improve healthcare efficiency and reduce medication shortages.

Addressing medication shortages requires a collaborative effort among government agencies, healthcare providers, manufacturers, and patients.

The FDA reported that the shortage began when Accord Healthcare shut down due to compliance issues with good manufacturing practices.

Pfizer and other manufacturers are increasing production to meet the demand.

Healthcare providers make treatment decisions based on disease aggressiveness and drug availability.

Hospital pharmacists manage shortages by offering alternatives, adjusting purchases, and rationing medicines.

About two-thirds of pharmacists said shortages were 'moderately impactful', affecting patients despite being manageable.

Shortages have forced 1 in 3 health systems to delay or alter patient care.

Patients are at risk when there are no alternatives to the affected drugs.

The FDA is allowing overseas imports of some chemotherapy drugs to address shortages.

Over a dozen cancer drugs, including cisplatin and carboplatin, are in short supply.

Cisplatin and similar drugs are prescribed for 10% to 20% of cancer patients.

Most academic cancer centers reported shortages of carboplatin (93%) and cisplatin (70%).

Cancer hospitals try to ensure sufficient medication during shortages.

Shortages also affect steroids, hormonal drugs, and oral liquids, not just chemotherapy drugs.

The American Society of Health-System Pharmacists (ASHP) is urging Congress to address medication shortages.

There are 309 reported drug shortages, nearing the record 320 in 2014.

Medication shortages are affecting people with chronic diseases like heart disease, diabetes, and kidney disease.

The shortage of medicines and medical supplies has led to a shortage of intensive care beds and emergency department capacity in hospitals.

Chronic disease patients have delayed treatment due to medication shortages, leading to complications requiring emergency hospitalization.

Heavy pressure on hospitals is causing treatment delays and further complications.

The medical sector lacks sufficient dollars to buy medicines and supplies.

The Ministry of Health must provide necessary medicines and supplies for chronic diseases.

Reviewing needs and facilitating procedures for state-funded or insured medication is necessary to address shortages.

Parliamentary action can address medication shortages affecting people with chronic diseases.

AI integration in biotechnology and healthcare can drive life-saving impact and increase experimental efficiency.

AI can make healthcare more efficient by addressing staff shortages, tackling fraud, and improving clinical practice.

Administrative spending accounts for 15-30% of medical spending, which AI-driven efficiency can help reduce.

The FDA needs to be empowered with AI to streamline review processes for medical products.

The FDA's 2019 Technology Modernization Action Plan aims to integrate emerging technology to drive efficiency.

Congress needs to work with the FDA to create a novel approval pathway for Software as Medical Devices that use LLMs and smaller models.

AI can help reduce bias in healthcare by using comprehensive data and continuous cross-checking.

The Coalition for Health AI is working with regulators to eliminate AI bias in healthcare.

Policymakers should promote bias prevention in AI-integrated healthcare rather than slowing its adoption due to bias concerns.

The Covid-19 pandemic has highlighted the effectiveness of alternative care delivery models in improving patient outcomes despite exacerbating staff shortages.

AI helps healthcare workers focus on patient care by reducing unnecessary paperwork.

AI can help patients compare costs and outcomes, enabling more informed purchasing of value-based care.

A record 323 drugs were in shortage in the first three months of 2024, affecting several countries including the US, France, Egypt, and India.

A record 323 drugs were in shortage in the first three months of 2024, affecting several countries including the US, France, Egypt, and India.

A record 323 drugs were in shortage in the first three months of 2024, affecting several countries including the US, France, Egypt, and India.

All drug classes are vulnerable to shortages, particularly sterile injectables, cancer chemotherapy, and emergency drugs.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
An Unexpected Catastrophe in the World ’ s Largest Country: The Complete Story of U.S. Drug Shortages
The deficit is at a record level.
According to data from the American Society of Health System Pharmacists and the University of Utah Drug Information Service, organizations began tracking drug shortages for the first time in 2001. Steady since 2021 – now reaching a record high of 323 drugs in the first three months of 2024.
Paul Abramowitz, CEO of the American Society of Health System Pharmacists, wrote in a blog post on Thursday: “It ’ s been a long time to end drug shortages, ” and wrote:“ All drug classes are vulnerable to shortages, some of the most worrisome shortages include sterile injectable generic drugs, including cancer chemotherapy drugs and emergency drugs stored in hospital vans and procedural areas. It is dangerous for doctors and patients. ”
In addition to the 32 chemotherapy drugs that are deficient, the five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, and intravenous fluids. [1] The Drug Deficiency Database maintained by the American Society of Health System Pharmacists and the University of Utah is based on voluntary reports from practitioners, patients, and others that have been confirmed by manufacturers. The U.S. drug is in short supply, because it captures broader effects on service providers and patients.
The crisis has lasted a year and a half.
More than half of the treatment shortages have lasted for more than two years, according to an analysis by health consultancy IQVIA, and the average shortage affects at least half a million patients, many of them elderly, according to the US Office of Health and Human Services under the Assistant Secretary for Planning and Evaluation, which shared its analysis with Congress in May.
Growing demand can play a role in drug shortages, as with the recent shortage of weight-loss drugs, but often manufacturing and quality problems, such as supply chain gaps and downtime, are the root cause. And varied.
But the American Society of Health System Pharmacists has “serious concerns ” about parts of this proposal, especially financial sanctions imposed on hospitals that lack the resources to comply with the recommendations, Abramowitz wrote:“ We all know that managing shortages is not enough and is not a sustainable solution to the worsening crisis, and there is still a lot of work to be done at the federal level to fix the root causes of drug shortages. ”
Why Shortage Occurs
Shortages can be caused by high demand, as with the recent shortage of weight-loss drugs, but this is not usually the main problem.
The FDA also blames manufacturing and quality problems, supply chain gaps, and downtime, and Dr. Emily Tucker, a drug shortage expert and an assistant professor of industrial engineering at Clemson University, says that when there is an indication of shortages, large health systems often also proactively place large orders, adding to the system ’ s stress.
“I don ’ t blame anyone.
“When I talk to all the stakeholders – whether it ’ s wholesalers, manufacturers, or the government – everyone wants this problem to end, ” she said.
Lack of transparency
Dr. Julie Grallo, chief medical officer and executive vice president of the American Society of Clinical Oncology, told the House Committee earlier that the shortage puts providers in a terrible position: “The drug shortage crisis is forcing providers to make impossible choices, and it is also hindering the development of new drugs. Health drugs are purchased only on a price basis, and manufacturers do not have to disclose the source of their acquisition of the ingredients.
The shortage of this generic chemical drug came due to the closure of one factory in India that manufactures the active ingredient after a surprise FDA inspection found “significant quality issues, ” says Jarallo:“ We didn ’ t know, and there was no transparency regarding the company ’ s supply of the majority of active pharmaceutical ingredients to all manufacturers across the board.
Knowing this in advance, we could have responded much faster, ” Dr. Steven Schundlemeyer, director of the PRIME Institute of the University of Minnesota School of Pharmacy, which focuses on economic and management issues, told the committee that as with defense contractors in the United States, New Zealand requires manufacturers to disclose their suppliers, and that information is required.
Easily accessible in the database.
Related Topics

The five categories of drugs with the greatest deficiency include central nervous system stimulants, antimicrobials, hormonal agents, intravenous fluids, and 32 chemotherapy drugs.

Most treatment shortages last over two years, affecting at least half a million patients, often elderly.

Manufacturing and quality problems are often the root cause of drug shortages, rather than just growing demand.

The FDA blames manufacturing issues, supply chain gaps, and downtime for drug shortages.

Large health systems often place large orders at the first sign of shortages, adding to the stress.

Lack of transparency in the supply chain can exacerbate drug shortages.

Requiring manufacturers to disclose suppliers, like in New Zealand, could help address drug shortages by increasing supply chain transparency.

The American Society of Health System Pharmacists has concerns about a proposal to address drug shortages, citing unfair financial sanctions on under-resourced hospitals.

Managing shortages is not enough and more federal work is needed to address the root causes of the crisis.

The White House proposes spending $3.26 billion to $5.11 billion over the next decade to address the nation's drug shortage.

Title:

Content: Meitu
The first quarter of the United States serious drug shortage 323 drugs urgent cancer patients also have to be diverted and rationed!
CHU HENG NETWORK NEWS CENTER 2024-04-16 10: 42
According to the latest data from the American Society of Health System Pharmacists (ASHP) and the Utah Center for Drug Information Services, a total of 323 drugs in the United States were in severe shortages in the first quarter of this year, surpassing the record of 320 in 2014.
Among the drugs affected are the widely used diabetes drugs Ozempic and Mounjaro, the allergy treatment drug adrenaline, the common antibiotic amoxicillin for children, chemotherapy drugs and injections commonly used in hospitals in intensive care.
ASHP CEO Paul Abramowitz said in a statement that almost all categories of drugs are facing shortages, with non-patented sterile injectable drugs, including cancer chemotherapy drugs, and emergency drugs stored in hospital emergency vans and operating areas, the shortage of such drugs is the most worrying.
According to the American Cancer Society, chemotherapy is one of the top five drugs most affected by the shortage, which threatens to have a devastating impact on patients, and some hospitals and clinics say doctors have had to divert patients to ration their medications because of a shortage of some chemotherapy drugs.
In addition, ASHP noted that the continued nationwide shortage of ADHD drugs is “a problem for clinicians and patients. ”
The shortage of popular drugs is even more acute, with Mounjaro, the diabetes drug known as the “slimming pill ”, already in dire straits.
In response, Lilly said that the “unprecedented surge in demand ” for Mounjaro and its similar drug Zepbound has led to a shortage in the market, which the company is struggling to cope with.
Lilly is ramping up investments to boost production at Mounjaro and Zepbound in the second half of 2024.
The company said it expects intermittent supply disruptions in the near term due to unprecedented demand.
How to cure the drug shortage
The last major “drug shortage ” in U.S. history occurred in 2014, and it has only been alleviated in the years since.
Since 2021, the drug shortage situation seems to be increasing, and scholars in the field of medical health and economics in the United States believe that the reason for most drug shortages in the United States is the fragmentation of the drug supply chain.
The White House this month proposed spending between $3.26 billion and $5.11 billion over the next decade to help address the nation ’ s drug shortage.
The bill requires approval and funding from the U.S. Congress.
U.S. researchers and policymakers believe that a complete solution to the “drug shortage ” may require changes to the business model of the U.S. pharmaceutical industry, including measures to increase the price of generic drugs to attract more drug manufacturers.
Policymakers recommend giving the FDA more power to access more information about drug shortages and impending shortages.
Currently, the FDA relies primarily on phone calls to manufacturers asking if they can increase their supply to understand the situation.
The American Society of Health System Pharmacists said it is working with the federal government to advise the government on measures to address the drug shortage, including that Congress should require manufacturers to be more transparent on any supply chain issues and encourage more diversity in supply chains.
According to Abramowitz, “The federal government still has a lot of work to do to fundamentally address drug shortages, and the American Society of Health System Pharmacists will continue to engage regularly with policymakers to guide them in drafting and passing new legislation to address drug shortages and continue to advocate vigorously for proven solutions on behalf of our members. ”

Policymakers recommend giving the FDA more power to access drug shortage information.

The American Society of Health System Pharmacists is working with the federal government to address the drug shortage by promoting supply chain transparency and diversity.

The price of an imported insulin pen in Egypt has risen from 62 to 192 pounds due to a shortage.

Title:

Content: The Egyptian alternative is not available.. and the importer increased 150% search for insulin..
A journey of misery that threatens the lives of diabetic patients
5.
There is no voice louder than the cries of patients who have failed to get their medicine.. The crisis of lack of medicines continues and haunting patients and threatening their lives.. The most prominent shortcomings of insulin.. In the new republic, access to insulin has become a difficult dream.
Insulin disappeared from pharmacies.. The Right to Medicine Association also received many complaints about the lack of insulin in public hospitals and health insurance clinics in the provinces.
Some patients resorted to the ambulance pharmacy in search of insulin, which is dispensed in specific quantities after providing a modern prescription and analysis proving the patient's diabetes, which prompted citizens to crowd in front of the ambulance pharmacy in long queues to buy those shortcomings after they disappeared from all pharmacies.
The lack of insulin prompted a number of patients to share their suffering on the social networking site Facebook and wondered where it was available.
The price of imported insulin pen rose from 62 pounds to 100 pounds and then 150 pounds up to 192 pounds.. The local price reaches 40 pounds, but it is not available only in the ambulance pharmacy and the patient spends one pen after submitting the prescription and a copy of the card and the analysis that proves the disease.
The crisis is not limited to pharmacies and government and university hospitals, but there is a shortage of insulin in health insurance pharmacies.
Many diabetic patients have complained of not being able to dispense their monthly treatment due to the lack of insulin.. The patient also has to pass through many pharmacies on a long journey to dispense his treatment and there are some pharmacies that dispense half the dose only because of the existing shortage.
The government held several meetings to discuss the drug shortage crisis and promised to solve it within a week.
The crisis prompted a number of deputies to submit requests for a briefing in the House of Representatives on the crisis of the shortage of medicines for chronic diseases such as heart, pressure and diabetes … and accused the Unified Procurement Authority and the Ministry of Health of failing to resolve the crisis.
Mohamed Elbahi, consultant of the Chamber of Pharmaceutical Industry at the Federation of Industries, said that the shortage of medicines in Egypt is caused by the high prices of raw materials due to the high exchange rate, as most of the raw materials used in the pharmaceutical industry are imported from abroad.
I forgot to solve the crisis in stages so as not to impose a burden on the citizen and expect the end of the crisis of medicine shortages within three months at the latest.
Although Egypt imports a large amount of insulin, the Minister of Health and Population, Dr. Khaled Abdel Ghaffar, said in statements that Egypt is a producer of insulin, and local insulin can be used as an alternative to the importer, but it is also not available.
As pointed out by dr.
Alaa Mohamed, a pharmacist, said that there is a prevailing culture among citizens that the importer is the best and despite the high price of imported insulin, but the patient is still looking for him and is not satisfied with the alternative.. There are patients suffering from diabetes for several years and they are accustomed to the importer and it is difficult to replace it with the Egyptian.
Dr. Ali Abdullah, director of the Center for Pharmaceutical Studies, explained that the reason for the shortage of medicines is the inability of the producing companies to bear the difference of money to import raw materials after the rise of the dollar price from 31 pounds to 49 pounds.
He pointed out the need to raise the awareness of citizens and change the prevailing culture that the importer is better than the local. We must educate patients to use alternative medicines because they are much cheaper than the importer, which costs us a lot of money.
He added that it is necessary to enact legislation to prevent the dispensing of medicines without prescription in order to prevent the withdrawal of medicines and their use for purposes other than those specified for them.
On the other hand, Dr. Ali Abdullah called for the need to reconsider the pricing of medicines with not forgetting the social and investment part of companies.. And the citizen to accept the increase in the prices of medicine, and also must control the market of medicines.. There are statements by Minister Dr. Khaled Abdel Ghaffar pointed out that the private sector represents 70% of medicines, and the government has 30%.. Unfortunately there is a large amount of government medicines private hospitals and pharmacies health insurance are leaked For the black market and the citizen does not find evidence in a syringe price of 200 pounds sold for 2000 pounds.. In a drug used in illegal abortion price of 11 pounds is now sold for 200 and 300 pounds although it is private government only.. And on the private level we find abuse in the use of drugs veterinarians sell veterinary drugs with feed..
And gynecologists and obstetricians sell the IUD at times its prices and hormonal injections as well.. Where is the legislation that governs this farce and where is the drug traceability that governs the medicine can.
Dr. Irene Saad, a member of the House of Representatives, pointed out that the reason for the shortage of medicines, especially medicines for chronic diseases, is the decline in the import of raw materials and the tendency of some factories and companies to stop production lines because of the lack of raw materials for the industry due to the high price of the dollar.
She stressed that the role of the state is to pay attention to the factories of the private business sector in the country, which can feed the gap in public hospitals and health insurance, and there is more interest in the city of medicine to serve the national industry, and there is a national strategy to localize the drug industry and rely on local alternatives.
It is possible to agree with the Ministry of Agriculture to provide animal gelatin.. Packaging materials.. Manufacturing these materials locally can save the final cost and reach a fair price for medicines..
Therefore, the state should give incentives to important production lines that fill a deficit.. There must be coordination between the Pharmaceutical Authority and the Ministry of Industry to identify the shortcomings and develop alternative plans to provide them at reasonable prices.
She pointed out that insulin, for example, from medicines should be in stock at least 6 months because of its great importance in providing health care to citizens, and there should be stock for all medicines, especially medicines for chronic diseases.

Insulin costs 40 pounds locally, but is only available by prescription at the ambulance pharmacy for those with proven diabetes.

Egypt's medicine shortage is caused by high raw material prices due to a high exchange rate, as most are imported.

Egypt produces insulin, but the local product is not widely available.

Citizens' preference for imported medicines contributes to a shortage of local alternatives.

The director of the Center for Pharmaceutical Studies has called for awareness about local medicines and legislation to prevent over-the-counter dispensing without a prescription.

The private sector dominates Egypt's medicine market at 70%, with the government holding 30%, although much of its share is lost to the black market.

The high dollar price has led some factories to halt production, contributing to a medicine shortage, particularly for chronic diseases.

The state is urged to support private sector factories and develop a national strategy to localize the drug industry.

Essential medicines, including insulin, should be stockpiled for at least 6 months.

Activists and health experts have appealed to Prime Minister Narendra Modi to address India's ongoing anti-TB drug shortages.

Title:

Content: Advertisment

TB and HIV Advocates Appeal to PM Modi Over Anti-TB Drug Shortages Ahead of World TB Day

Activists and health experts urgently request PM Modi's intervention on the eve of World TB Day to address the ongoing anti-TB drug shortages across India.

BNN Correspondents
New Update

In a significant plea for intervention, activists, public health experts, tuberculosis survivors, and individuals living with HIV have sent a distress letter to Prime Minister Narendra Modi on the eve of World TB Day, urgently requesting his attention to the ongoing shortages of anti-TB drugs across India. This call to action underscores the dire situation for those afflicted by tuberculosis, emphasizing the need for immediate governmental response to prevent further health crises.

Advertisment

Urgent Call for Governmental Action

The letter addressed to PM Modi detailed the specific anti-TB drugs currently in shortage, particularly those vital for treating drug-sensitive tuberculosis (DS-TB). The activists highlighted the grave implications of these shortages, including treatment disruptions and the heightened risk of drug-resistant TB strains. This situation not only jeopardizes the health of individuals currently undergoing treatment but also poses a significant threat to public health at large. The communication also shed light on the logistical challenges and bureaucratic delays in drug procurement at the state level, further exacerbating the issue.

Impact on Treatment and Patient Lives

Advertisment

The consequences of these drug shortages are far-reaching, affecting TB patients' ability to adhere to their treatment regimens. Many are forced to make repeated visits to health centers, often at the cost of their day's wages, posing a harsh dilemma between earning a livelihood and seeking life-saving treatment. The letter poignantly outlines the predicament faced by those who, due to the unavailability of drugs, might have to purchase medication out-of-pocket, a financial burden too heavy for many to bear. This crisis highlights the urgent need for a streamlined and effective response to ensure the availability of essential TB medications.

Previous Denials and A Call for Transparency

Despite previous denials from the Health Ministry regarding the existence of such shortages, the persistence of this issue speaks volumes. The activists' letter calls for a transparent and accountable approach to addressing these shortages, urging the government to undertake emergency procurement measures and ensure the uninterrupted supply of these critical drugs. As the country with the highest burden of tuberculosis globally, India's response to this crisis will be closely watched by the international community and public health advocates alike.

As World TB Day approaches, this urgent appeal to Prime Minister Modi serves as a reminder of the ongoing struggles faced by those living with tuberculosis and HIV in India. The resolution of the anti-TB drug shortage crisis not only requires immediate governmental intervention but also a long-term commitment to strengthening India's healthcare infrastructure to prevent such situations in the future. The health and well-being of millions hang in the balance, awaiting decisive action.

Advertisment
Advertisment

The shortages are affecting drugs for treating drug-sensitive tuberculosis.

The shortages have grave implications, including treatment disruptions and increased risk of drug-resistant TB.

State-level logistical and bureaucratic issues are exacerbating the problem.

TB patients face challenges adhering to treatment due to drug shortages.

Many patients face a financial burden from buying medication out-of-pocket due to drug unavailability.

The persistence of the issue highlights the need for a transparent and accountable approach to addressing the shortages.

The government is being urged to ensure an uninterrupted supply of critical TB drugs.

India has the highest global burden of tuberculosis, drawing international attention to its response.

Resolving the anti-TB drug shortage crisis requires immediate governmental intervention and a long-term commitment to strengthening India's healthcare infrastructure.

Title:

Content: Advertisment

TB and HIV Advocates Appeal to PM Modi Over Anti-TB Drug Shortages Ahead of World TB Day

Activists and health experts urgently request PM Modi's intervention on the eve of World TB Day to address the ongoing anti-TB drug shortages across India.

BNN Correspondents
New Update

In a significant plea for intervention, activists, public health experts, tuberculosis survivors, and individuals living with HIV have sent a distress letter to Prime Minister Narendra Modi on the eve of World TB Day, urgently requesting his attention to the ongoing shortages of anti-TB drugs across India. This call to action underscores the dire situation for those afflicted by tuberculosis, emphasizing the need for immediate governmental response to prevent further health crises.

Advertisment

Urgent Call for Governmental Action

The letter addressed to PM Modi detailed the specific anti-TB drugs currently in shortage, particularly those vital for treating drug-sensitive tuberculosis (DS-TB). The activists highlighted the grave implications of these shortages, including treatment disruptions and the heightened risk of drug-resistant TB strains. This situation not only jeopardizes the health of individuals currently undergoing treatment but also poses a significant threat to public health at large. The communication also shed light on the logistical challenges and bureaucratic delays in drug procurement at the state level, further exacerbating the issue.

Impact on Treatment and Patient Lives

Advertisment

The consequences of these drug shortages are far-reaching, affecting TB patients' ability to adhere to their treatment regimens. Many are forced to make repeated visits to health centers, often at the cost of their day's wages, posing a harsh dilemma between earning a livelihood and seeking life-saving treatment. The letter poignantly outlines the predicament faced by those who, due to the unavailability of drugs, might have to purchase medication out-of-pocket, a financial burden too heavy for many to bear. This crisis highlights the urgent need for a streamlined and effective response to ensure the availability of essential TB medications.

Previous Denials and A Call for Transparency

Despite previous denials from the Health Ministry regarding the existence of such shortages, the persistence of this issue speaks volumes. The activists' letter calls for a transparent and accountable approach to addressing these shortages, urging the government to undertake emergency procurement measures and ensure the uninterrupted supply of these critical drugs. As the country with the highest burden of tuberculosis globally, India's response to this crisis will be closely watched by the international community and public health advocates alike.

As World TB Day approaches, this urgent appeal to Prime Minister Modi serves as a reminder of the ongoing struggles faced by those living with tuberculosis and HIV in India. The resolution of the anti-TB drug shortage crisis not only requires immediate governmental intervention but also a long-term commitment to strengthening India's healthcare infrastructure to prevent such situations in the future. The health and well-being of millions hang in the balance, awaiting decisive action.

Advertisment
Advertisment

The current system for addressing medication shortages is insufficient.

This can include increasing supply chain transparency, improving manufacturer-provider communication, and supporting affected patients.

Policymakers can address the root causes of medication shortages and develop prevention strategies.

Technology, like artificial intelligence, can improve healthcare efficiency and reduce medication shortages.

Title:

Content: Washington: Will You Let AI Make Us Healthier?

The world is amidst an AI-driven industrial revolution. As a16z cofounder Marc Andreessen recently wrote, AI will save the world. The United Kingdom just staked its claim on the AI frontier, challenging US policymakers to reaffirm America’s role as the powerhouse of tech innovation. Whether we let it improve the health of Americans is up to how we regulate it.

There is no sector where AI can drive more immediate, life-saving impact than in biotechnology and healthcare. In bio, AI will enable our scientists to conduct experiments faster and more efficiently than ever before, resulting in better treatments for patients suffering from debilitating diseases. In health, AI will enable our care providers to tend to more patients with greater precision and less burnout, resulting in better consumer experiences and health outcomes. In our communities, AI will enable people to live healthier, happier lives with their families and loved ones. Patients are poised to reap immense benefits from AI integration into the biotech and healthcare sectors. Broad implementation will democratize access to high quality care.

As policymakers grapple with the integration of AI into life sciences and care delivery, it is essential that they work closely with industry to consider how potential regulations will enable a vibrant and competitive marketplace and maximize patient welfare. At a16z, we’re fortunate to work with many of the most innovative, forward-leaning companies shaping the future of AI, affording us a unique vantage point to anticipate the landscapes of tomorrow.

Like many areas where AI technology is being used, regulatory frameworks already exist, and healthcare is no different. The federal government has been regulating software-based medical products since the 1970s. As policymakers face calls for regulation of artificial intelligence in the biotech and healthcare sectors, they must consider these important themes to prevent stifling innovation and incentivize investment at home.

Here are 3 things regulators should do to prepare for the AI revolution in bio and health:

1. Empower the FDA with AI as a tool

A tidal wave of investigational new drug (IND) applications is headed for the FDA. AI advancements in drug discovery and development are driving diminishing research timelines and R&D costs while streamlining clinical trial design, recruitment, and enrollment. Without more streamlined IND, BLA, and NDA review processes or a drastic increase in personnel, the FDA could quickly fall behind, which could significantly delay review timelines and patient access to new lifesaving therapeutics.

IND applications have increased significantly in recent years. As the Agency scales in order to meet the growing need, one way to alleviate bottleneck issues is to leverage AI for data review.

The FDA’s 2019 Technology Modernization Action Plan put in place the framework for the FDA to begin working to integrate emerging technology internally to drive efficiency and bring the organization up to speed with the industries it regulates. The FDA needs to double down on this effort and aggressively push to integrate AI as standard practice for data evaluation for medical product review for new applications and post-approval, postmarket review. In order to leverage this tech, the FDA should rapidly recruit new staff that are trained in data and software, AI and ML engineering, data science, and even mechanical engineering.

The Digital Health Center of Excellence also needs to spearhead the implementation of AI and advanced software programs internally to facilitate more aggressive integration and efficient product review across the medical product centers.

At the same time, Congress must work with the FDA to create a novel Software as Medical Device approval pathway capable of reviewing applications that leverage both foundational LLMs and specialty, smaller models. To do this, the Agency will need to require a baseline approval of the foundational model, and a less rigorous review for the smaller, specialty models, which will be subject to postmarket surveillance.

The FDA must be flexible, dynamic, and ready to embrace these new technologies.

2. Let AI drive dollars to patient care

From addressing staff shortages to tackling fraudulent claims to helping clinicians practice more effectively, AI can help make our healthcare system more efficient and cost-effective. According to a recent analysis in Health Affairs, administrative spending accounts for between 15 and 30 percent of medical spending. AI-driven efficiency in hospital workflows and documentation, implementation of payment policy, and claims review processes will help save dollars currently spent on manual, clerical work. This can free up resources to provide patient care, which will drive better health outcomes and enhance patient engagement. Policymakers and regulators need to work together to ensure the potential benefits of the AI revolution result in better outcomes that patients and providers can both experience and appreciate.

The Covid-19 pandemic exacerbated staff shortages in the healthcare system, but it also showed that different models of care delivery can be effective and safe, and lead to improved patient outcomes. In addition to prioritizing recruitment and retention of healthcare personnel, Congress should promote AI to enable healthcare workers to do their job more effectively and efficiently, ensuring that their time is focused on care delivery to patients and not unnecessary paperwork.

AI can also benefit Congress’ drive toward price transparency and may allow patients to compare costs and outcomes to become more prudent purchasers of value-based care. AI is already streamlining data procurement, aggregation, and reporting. It is part of a movement to give patients more ownership over their health data and to use their data more effectively to manage their clinical needs and costs. Policymakers and regulators should utilize appropriate enforcement authority that balances the need to avoid harm to patients and the public, while incentivizing the development and implementation of AI-based interventions that can improve outcomes and reduce costs.

3. Enable data to surmount bias

Algorithmic bias in AI has received significant attention from the Biden Administration. The White House’s Blueprint for an AI Bill of Rights included a discussion on bias alleviation standards, and HHS included a bias alleviation proposal in a recent proposed rule.

Bias is a knock-on effect of the data used to train the AI model; because the healthcare system has inequities in care, these inequities can be reproduced in data and therefore in AI models built on that data. But this isn’t an inevitability. As Dr. Mark Sendak of the Duke Institute for Health Innovation told NPR (and Dr. Micky Tripathi, the National Coordinator for Health Information Technology at HHS emphasized on Twitter), addressing bias requires “look[ing] in the mirror.” He noted that addressing this bias “requires you to ask hard questions of yourself, of the people you work with, the organizations you’re a part of. Because if you’re actually looking for bias in algorithms, the root cause of a lot of the bias is inequities in care.”

In other words: any type of bias is a legitimate concern. But bias in AI is not insurmountable—it can be addressed with comprehensive data, plus continuous cross-checking of the data for bias and evaluation of the performance of the derivative algorithms. If bias is found in the output of an algorithm, go back and check the data.

Providers, academic medical centers, and industry are working together with regulators through the Coalition for Health AI to promote ways that the federal government can eliminate AI bias. For example, providing a food nutrition-like label with clinical decision support software that could ensure providers are aware of the specific patient populations that would benefit from use of an AI-powered algorithm. Policymakers and regulators should not slow down AI-integration in health care for fear of bias. They must promote bias prevention, detection, and mitigation.

Don’t stand in the way of AI getting smarter

You’ve heard the warnings about AI. Like any new technology, AI offers both opportunities and challenges. The AI doomsday scenario preys upon our natural human fears that unscrupulous individuals will leverage good technology to do bad things. In healthcare, however, legislators have a once-in-a-lifetime opportunity to safely and effectively usher the most significant advancement of our time in life sciences and healthcare. For those who joined government to leave a lasting legacy and positive impact on humanity, AI is your chance. Let’s leverage AI to make Americans healthier.

***

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

Biology is eating the world

Sign up for our bio newsletter to get the a16z take on the future of biology and engineering.

Addressing medication shortages requires a collaborative effort among government agencies, healthcare providers, manufacturers, and patients.

The FDA reported that the shortage began when Accord Healthcare shut down due to compliance issues with good manufacturing practices.

Title:

Content: NORTHAMPTON, Mass. (WWLP) – While this shortage of chemotherapy drugs stretches across the country, 22News looks at how the limited amounts of potentially life-saving drugs are impacting cancer care in our area.

It’s a problem, so acute it was recognized by the Biden Administration just last month. The White House noted there’s a shortage of 15 cancer drugs due to manufacturing and supply chain issues.

22News asked Pharmacy Director Michelle Kososki at Mass General Brigham Cooley Dickinson Hospital, to rate the shortage experienced locally on a scale, 5 being a critical shortage and 1 being no shortage at all, “right now I would probably say it is a four. We only have a very small supply of one particular drug.”

Pharmacy Director Michelle Kososki said drug shortages are not uncommon in the healthcare industry however, when faced with potentially life-saving drugs it can get complicated, “Anytime there is a shortage, there’s a risk of not being able to treat patients. Obviously, that is something we want to avoid and we work to the best of our ability with creative solutions to make sure that doesn’t happen.”

Nurse Manager Lisa Martensson at Mass General Care Center at Cooley Dickinson Hospital told 22News, “There’s always the ethical issues of who gets the drug that’s available. It’s supply and demand as you said and looking at what folks had for their disease which ones needed to be treated faster than others based on the aggressiveness of their disease. Those things played in but it was a really difficult decision to sit down and try and decide who would get the drug. We were never in a position where we had to deny anybody.”

Cancer patient Norman Uzdavinis of Whately said he was very concerned when he first heard of the shortage, “I had wondered where in the chemotherapy I would be at, would it have to be delayed for months or years if possible.”

Uzdavinis has not had his medical care compromised but feels for those who have, “I feel for them. I know what I’m going through and that everything is here so it’s perfect for me, but there’s a lot out there that are not as fortunate. I know that.”

“Healthcare providers here were able to mitigate the shortage by using a couple of different tactics. For example, they could switch up a patient’s medication regimen,” Nurse Manager Lisa Martensson said.

“What we did do was use drugs that were in the same classification but not necessarily that specific drug. There are also drug regimens where we could switch around the order to which we gave the drugs so if there was a drug that wasn’t available we are able to do one of the drugs that was available first and do that second drug second. That was able to work out so people didn’t do without and they were able to get what they needed,” Martensson continued.

According to the FDA, the shortage started when one of the major manufacturers of the chemo drug, Accord Healthcare, a company based in India, had to shut down after problems complying with good manufacturing practices were found during an inspection. Now, there is an increased demand from other companies that make these kinds of drugs.

22News contacted some other of the manufacturers of these drugs. Pfizer said they are increasing production by about 40 percent to meet this increased demand.

Local News

Alanna Flood is a reporter who has been a part of the 22News team since 2022. Follow Alanna on X @alannafloodnews and view her bio to see more of her work.

Pfizer and other manufacturers are increasing production to meet the demand.

Healthcare providers make treatment decisions based on disease aggressiveness and drug availability.

Hospital pharmacists manage shortages by offering alternatives, adjusting purchases, and rationing medicines.

Title:

Content: As drug shortage list grows, many hospitals face tough decisions on rationing care

More than half of hospital pharmacists are reporting a critical shortage of chemotherapy drugs and nearly all are reporting overall medicine supply gaps as prescription drug shortages near an all time high, according to a new survey.

Hospital pharmacists said drug shortages have forced 1 in 3 health systems to delay, cancel or ration care or switch to alternate drugs to continue to treat patients. And 99% are reporting some drug supply shortages, an American Society of Health-System Pharmacists survey of more than 1,000 pharmacists released Thursday found.

The organization reported shortages of 309 drugs, near the all-time high of 320 shortages in 2014. The scarcity of key drugs is prompting hospitals to find or substitute drugs and change treatment plans as needed.

“In some cases, there are no alternatives to the affected drugs, which puts patients at risk," ASHP Chief Executive Officer Paul W. Abramowitz said in a statement. "This issue requires quick action from Congress to address the underlying causes of shortages and ensure patients have the medications they need.”

Cancer drug shortages

In June, the Food and Drug Administration said it will temporarily allow overseas drug manufacturers to import some chemotherapy drugs.

The FDA allowed Qilu Pharmaceutical, a drug manufacturer in China, to import the injectable chemotherapy drug cisplatin in 50-milligram vials. Toronto pharmaceutical company Apotex Corp. will distribute the medication in the United States.

More than a dozen cancer drugs have been in shortage in recent months, including cisplatin and carboplatin, used to treat lung, breast, prostate and gynecologic cancers. The National Cancer Institute said cisplatin and similar drugs are prescribed for 10% to 20% of all cancer patients.

In June, the National Comprehensive Cancer Network released a survey of 27 academic cancer centers that found 93% reported shortages of carboplatin and 70% faced shortages of cisplatin.

When cancer hospitals face such shortages, they attempt to make sure there's enough medication for patients to finish the course of treatment, said Mike Ganio, ASHP's senior director of pharmacy practice and quality.

Cancer hospitals facing such shortages might change medications for new patients starting on chemotherapy, said Ganio, a former pharmacy manager at an academic cancer center.

"You try to keep that patient on the same regimen as much as you can, unless they're failing it for some reason, and then you would switch," Ganio said.

Steroids, hormonal drugs also in short supply

More than 1 in 5 hospital pharmacists also reported shortages for steroids, hormonal drugs and oral liquids such as lidocaine, ibuprofen and amoxicillin.

A smaller number of pharmacists said heart medications, emergency prefilled syringes and drugs used for intensive care unit patients were in short supply. Others reported shortages of attention deficit hyperactivity disorder medicines, antimicrobial drugs and injectable opioids.

In all, about two-thirds of pharmacists said the shortages were "moderately impactful," which means they are managing shortages but patients are affected.

Pharmacists are managing the shortages by offering therapeutic alternatives, buying different vial sizes or concentrations and rationing medicines.

This article originally appeared on USA TODAY: Survey: Drug shortages are widespread, hospitals ration care

About two-thirds of pharmacists said shortages were 'moderately impactful', affecting patients despite being manageable.

Shortages have forced 1 in 3 health systems to delay or alter patient care.

Patients are at risk when there are no alternatives to the affected drugs.

The FDA is allowing overseas imports of some chemotherapy drugs to address shortages.

Over a dozen cancer drugs, including cisplatin and carboplatin, are in short supply.

Cisplatin and similar drugs are prescribed for 10% to 20% of cancer patients.

Most academic cancer centers reported shortages of carboplatin (93%) and cisplatin (70%).

Cancer hospitals try to ensure sufficient medication during shortages.

Shortages also affect steroids, hormonal drugs, and oral liquids, not just chemotherapy drugs.

The American Society of Health-System Pharmacists (ASHP) is urging Congress to address medication shortages.

There are 309 reported drug shortages, nearing the record 320 in 2014.

Medication shortages are affecting people with chronic diseases like heart disease, diabetes, and kidney disease.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Despite the availability of the dollar...
Parliamentary action on the suffering of people with chronic diseases due to the lack of treatment
Dr. Hisham Hussein, Secretary of the Suggestions and Complaints Committee of the House of Representatives, submitted a request for a briefing to Advisor Dr. Hanafi Jebali, President of the Council, addressed to the Prime Minister and Minister of Health and Population, on the continued shortage of medicines and medical supplies, despite the availability of the dollar, and the impact of this on people with chronic diseases.
Hisham Hussein pointed out that the past few days have witnessed a great problem in the insufficiency of intensive care beds and emergency departments in hospitals, due to the frequency of critical cases, which were unable to get the necessary treatment on the scheduled dates.
Hisham Hussein explained that many people with chronic diseases such as heart, kidney, tumors, diabetes and others delayed the payment of their scheduled treatment, whether from health insurance, or treatment at the expense of the state, which caused complications that led to their need to enter hospitals in emergency departments or non-intensive care.
The MP stressed that because of the heavy pressure on hospitals, many cases were unable to get the necessary treatment, which led to many complications and portends a great problem.
The member of the House of Representatives pointed out that many have pinned their hopes on the availability of the dollar in the past period, to meet the needs of the medical sector of medicines and supplies, saying: However, it seems that more action is needed in this regard.
Hisham Hussein called on the Ministry of Health, in coordination with the concerned authorities, to take the necessary measures to provide all medicines and medical supplies for the benefit of chronic diseases, by reviewing all needs, stressing the need to facilitate procedures to obtain medicines through health insurance or treatment at the expense of the state.

The shortage of medicines and medical supplies has led to a shortage of intensive care beds and emergency department capacity in hospitals.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Despite the availability of the dollar...
Parliamentary action on the suffering of people with chronic diseases due to the lack of treatment
Dr. Hisham Hussein, Secretary of the Suggestions and Complaints Committee of the House of Representatives, submitted a request for a briefing to Advisor Dr. Hanafi Jebali, President of the Council, addressed to the Prime Minister and Minister of Health and Population, on the continued shortage of medicines and medical supplies, despite the availability of the dollar, and the impact of this on people with chronic diseases.
Hisham Hussein pointed out that the past few days have witnessed a great problem in the insufficiency of intensive care beds and emergency departments in hospitals, due to the frequency of critical cases, which were unable to get the necessary treatment on the scheduled dates.
Hisham Hussein explained that many people with chronic diseases such as heart, kidney, tumors, diabetes and others delayed the payment of their scheduled treatment, whether from health insurance, or treatment at the expense of the state, which caused complications that led to their need to enter hospitals in emergency departments or non-intensive care.
The MP stressed that because of the heavy pressure on hospitals, many cases were unable to get the necessary treatment, which led to many complications and portends a great problem.
The member of the House of Representatives pointed out that many have pinned their hopes on the availability of the dollar in the past period, to meet the needs of the medical sector of medicines and supplies, saying: However, it seems that more action is needed in this regard.
Hisham Hussein called on the Ministry of Health, in coordination with the concerned authorities, to take the necessary measures to provide all medicines and medical supplies for the benefit of chronic diseases, by reviewing all needs, stressing the need to facilitate procedures to obtain medicines through health insurance or treatment at the expense of the state.

Chronic disease patients have delayed treatment due to medication shortages, leading to complications requiring emergency hospitalization.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Despite the availability of the dollar...
Parliamentary action on the suffering of people with chronic diseases due to the lack of treatment
Dr. Hisham Hussein, Secretary of the Suggestions and Complaints Committee of the House of Representatives, submitted a request for a briefing to Advisor Dr. Hanafi Jebali, President of the Council, addressed to the Prime Minister and Minister of Health and Population, on the continued shortage of medicines and medical supplies, despite the availability of the dollar, and the impact of this on people with chronic diseases.
Hisham Hussein pointed out that the past few days have witnessed a great problem in the insufficiency of intensive care beds and emergency departments in hospitals, due to the frequency of critical cases, which were unable to get the necessary treatment on the scheduled dates.
Hisham Hussein explained that many people with chronic diseases such as heart, kidney, tumors, diabetes and others delayed the payment of their scheduled treatment, whether from health insurance, or treatment at the expense of the state, which caused complications that led to their need to enter hospitals in emergency departments or non-intensive care.
The MP stressed that because of the heavy pressure on hospitals, many cases were unable to get the necessary treatment, which led to many complications and portends a great problem.
The member of the House of Representatives pointed out that many have pinned their hopes on the availability of the dollar in the past period, to meet the needs of the medical sector of medicines and supplies, saying: However, it seems that more action is needed in this regard.
Hisham Hussein called on the Ministry of Health, in coordination with the concerned authorities, to take the necessary measures to provide all medicines and medical supplies for the benefit of chronic diseases, by reviewing all needs, stressing the need to facilitate procedures to obtain medicines through health insurance or treatment at the expense of the state.

Heavy pressure on hospitals is causing treatment delays and further complications.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Despite the availability of the dollar...
Parliamentary action on the suffering of people with chronic diseases due to the lack of treatment
Dr. Hisham Hussein, Secretary of the Suggestions and Complaints Committee of the House of Representatives, submitted a request for a briefing to Advisor Dr. Hanafi Jebali, President of the Council, addressed to the Prime Minister and Minister of Health and Population, on the continued shortage of medicines and medical supplies, despite the availability of the dollar, and the impact of this on people with chronic diseases.
Hisham Hussein pointed out that the past few days have witnessed a great problem in the insufficiency of intensive care beds and emergency departments in hospitals, due to the frequency of critical cases, which were unable to get the necessary treatment on the scheduled dates.
Hisham Hussein explained that many people with chronic diseases such as heart, kidney, tumors, diabetes and others delayed the payment of their scheduled treatment, whether from health insurance, or treatment at the expense of the state, which caused complications that led to their need to enter hospitals in emergency departments or non-intensive care.
The MP stressed that because of the heavy pressure on hospitals, many cases were unable to get the necessary treatment, which led to many complications and portends a great problem.
The member of the House of Representatives pointed out that many have pinned their hopes on the availability of the dollar in the past period, to meet the needs of the medical sector of medicines and supplies, saying: However, it seems that more action is needed in this regard.
Hisham Hussein called on the Ministry of Health, in coordination with the concerned authorities, to take the necessary measures to provide all medicines and medical supplies for the benefit of chronic diseases, by reviewing all needs, stressing the need to facilitate procedures to obtain medicines through health insurance or treatment at the expense of the state.

The medical sector lacks sufficient dollars to buy medicines and supplies.

The medical sector lacks sufficient dollars to buy medicines and supplies.

The medical sector lacks sufficient dollars to buy medicines and supplies.

The Ministry of Health must provide necessary medicines and supplies for chronic diseases.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Despite the availability of the dollar...
Parliamentary action on the suffering of people with chronic diseases due to the lack of treatment
Dr. Hisham Hussein, Secretary of the Suggestions and Complaints Committee of the House of Representatives, submitted a request for a briefing to Advisor Dr. Hanafi Jebali, President of the Council, addressed to the Prime Minister and Minister of Health and Population, on the continued shortage of medicines and medical supplies, despite the availability of the dollar, and the impact of this on people with chronic diseases.
Hisham Hussein pointed out that the past few days have witnessed a great problem in the insufficiency of intensive care beds and emergency departments in hospitals, due to the frequency of critical cases, which were unable to get the necessary treatment on the scheduled dates.
Hisham Hussein explained that many people with chronic diseases such as heart, kidney, tumors, diabetes and others delayed the payment of their scheduled treatment, whether from health insurance, or treatment at the expense of the state, which caused complications that led to their need to enter hospitals in emergency departments or non-intensive care.
The MP stressed that because of the heavy pressure on hospitals, many cases were unable to get the necessary treatment, which led to many complications and portends a great problem.
The member of the House of Representatives pointed out that many have pinned their hopes on the availability of the dollar in the past period, to meet the needs of the medical sector of medicines and supplies, saying: However, it seems that more action is needed in this regard.
Hisham Hussein called on the Ministry of Health, in coordination with the concerned authorities, to take the necessary measures to provide all medicines and medical supplies for the benefit of chronic diseases, by reviewing all needs, stressing the need to facilitate procedures to obtain medicines through health insurance or treatment at the expense of the state.

Reviewing needs and facilitating procedures for state-funded or insured medication is necessary to address shortages.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Despite the availability of the dollar...
Parliamentary action on the suffering of people with chronic diseases due to the lack of treatment
Dr. Hisham Hussein, Secretary of the Suggestions and Complaints Committee of the House of Representatives, submitted a request for a briefing to Advisor Dr. Hanafi Jebali, President of the Council, addressed to the Prime Minister and Minister of Health and Population, on the continued shortage of medicines and medical supplies, despite the availability of the dollar, and the impact of this on people with chronic diseases.
Hisham Hussein pointed out that the past few days have witnessed a great problem in the insufficiency of intensive care beds and emergency departments in hospitals, due to the frequency of critical cases, which were unable to get the necessary treatment on the scheduled dates.
Hisham Hussein explained that many people with chronic diseases such as heart, kidney, tumors, diabetes and others delayed the payment of their scheduled treatment, whether from health insurance, or treatment at the expense of the state, which caused complications that led to their need to enter hospitals in emergency departments or non-intensive care.
The MP stressed that because of the heavy pressure on hospitals, many cases were unable to get the necessary treatment, which led to many complications and portends a great problem.
The member of the House of Representatives pointed out that many have pinned their hopes on the availability of the dollar in the past period, to meet the needs of the medical sector of medicines and supplies, saying: However, it seems that more action is needed in this regard.
Hisham Hussein called on the Ministry of Health, in coordination with the concerned authorities, to take the necessary measures to provide all medicines and medical supplies for the benefit of chronic diseases, by reviewing all needs, stressing the need to facilitate procedures to obtain medicines through health insurance or treatment at the expense of the state.

Parliamentary action can address medication shortages affecting people with chronic diseases.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Despite the availability of the dollar...
Parliamentary action on the suffering of people with chronic diseases due to the lack of treatment
Dr. Hisham Hussein, Secretary of the Suggestions and Complaints Committee of the House of Representatives, submitted a request for a briefing to Advisor Dr. Hanafi Jebali, President of the Council, addressed to the Prime Minister and Minister of Health and Population, on the continued shortage of medicines and medical supplies, despite the availability of the dollar, and the impact of this on people with chronic diseases.
Hisham Hussein pointed out that the past few days have witnessed a great problem in the insufficiency of intensive care beds and emergency departments in hospitals, due to the frequency of critical cases, which were unable to get the necessary treatment on the scheduled dates.
Hisham Hussein explained that many people with chronic diseases such as heart, kidney, tumors, diabetes and others delayed the payment of their scheduled treatment, whether from health insurance, or treatment at the expense of the state, which caused complications that led to their need to enter hospitals in emergency departments or non-intensive care.
The MP stressed that because of the heavy pressure on hospitals, many cases were unable to get the necessary treatment, which led to many complications and portends a great problem.
The member of the House of Representatives pointed out that many have pinned their hopes on the availability of the dollar in the past period, to meet the needs of the medical sector of medicines and supplies, saying: However, it seems that more action is needed in this regard.
Hisham Hussein called on the Ministry of Health, in coordination with the concerned authorities, to take the necessary measures to provide all medicines and medical supplies for the benefit of chronic diseases, by reviewing all needs, stressing the need to facilitate procedures to obtain medicines through health insurance or treatment at the expense of the state.

AI integration in biotechnology and healthcare can drive life-saving impact and increase experimental efficiency.

AI can make healthcare more efficient by addressing staff shortages, tackling fraud, and improving clinical practice.

Administrative spending accounts for 15-30% of medical spending, which AI-driven efficiency can help reduce.

The FDA needs to be empowered with AI to streamline review processes for medical products.

The FDA's 2019 Technology Modernization Action Plan aims to integrate emerging technology to drive efficiency.

Congress needs to work with the FDA to create a novel approval pathway for Software as Medical Devices that use LLMs and smaller models.

AI can help reduce bias in healthcare by using comprehensive data and continuous cross-checking.

The Coalition for Health AI is working with regulators to eliminate AI bias in healthcare.

Policymakers should promote bias prevention in AI-integrated healthcare rather than slowing its adoption due to bias concerns.

The Covid-19 pandemic has highlighted the effectiveness of alternative care delivery models in improving patient outcomes despite exacerbating staff shortages.

AI helps healthcare workers focus on patient care by reducing unnecessary paperwork.

AI can help patients compare costs and outcomes, enabling more informed purchasing of value-based care.